InVitria develops, makes and commercializes recombinant, scalable and sustainable proteins used to improve manufacturing performance for cell and gene therapy, vaccines, regenerative medicines, biopharmaceuticals and medical devices. These products improve productivity, reliability, safety and time to market for clinical products.

Plant-derived functional food ingredients and preservatives.

ExpressTec.bio develops new proteins using plant biotechnology to improve health and nutrition.

Ventria Bioscience innovated the first commercial recombinant proteins derived from a plant-based manufacturing system, The platform technology subsequently became ExpressTec LLC.

Supply chain software company connecting producers with their markets to optimize quality, logistics and efficiency. Sold to John Deere & Co.

Started business unit which developed pharmaceutical intermediates and functional food ingredients derived from plants. Established a strategic partnership with F. Hoffmann-La Roche (Roche) and formed a new joint venture business to commercialize products derived from plants. Developed strategy, recruited management team, and arranged joint venture financing. This business unit achieved significant EBITDA. This business began Cargill's entry into technology-oriented businesses backed by peer-reviewed and published clinical research.

Provided financing solutions including merger and acquisition, divestiture and financial advice for US-based technology and life science companies.